Cellebrite DI [CLBT] vs Klaviyo [KVYO] Detailed Stock Comparison
Cellebrite DI
NASDAQ
Loading...
Klaviyo
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Cellebrite DI wins in 6 metrics, Klaviyo wins in 11 metrics, with 0 ties. Klaviyo appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cellebrite DI | Klaviyo | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.09 | -192.76 | Klaviyo |
| Price-to-Book Ratio | 9.55 | 8.95 | Klaviyo |
| Debt-to-Equity Ratio | 5.47 | 9.04 | Cellebrite DI |
| PEG Ratio | 39.88 | -0.55 | Klaviyo |
| EV/EBITDA | 46.15 | -96.03 | Klaviyo |
| Profit Margin (TTM) | -34.56% | -6.19% | Klaviyo |
| Operating Margin (TTM) | 14.58% | -10.69% | Cellebrite DI |
| EBITDA Margin (TTM) | 14.58% | N/A | N/A |
| Return on Equity | -81.98% | -6.42% | Klaviyo |
| Return on Assets (TTM) | 5.95% | -5.05% | Cellebrite DI |
| Free Cash Flow (TTM) | $121.56M | $148.73M | Klaviyo |
| 1-Year Return | -6.01% | 0.28% | Klaviyo |
| Price-to-Sales Ratio (TTM) | 8.93 | 9.12 | Cellebrite DI |
| Enterprise Value | $3.44B | $8.76B | Klaviyo |
| EV/Revenue Ratio | 7.88 | 8.12 | Cellebrite DI |
| Gross Profit Margin (TTM) | 84.39% | 75.70% | Cellebrite DI |
| Revenue per Share (TTM) | $2 | $4 | Klaviyo |
| Earnings per Share (Diluted) | $-0.72 | $-0.24 | Klaviyo |
| Beta (Stock Volatility) | 1.27 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cellebrite DI vs Klaviyo Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cellebrite DI | 1.26% | 3.27% | 12.97% | -3.59% | -14.99% | -25.62% |
| Klaviyo | 2.47% | 4.26% | 0.06% | -2.76% | -21.17% | -21.30% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cellebrite DI | -6.01% | 235.83% | 66.87% | 66.87% | 66.87% | 66.87% |
| Klaviyo | 0.28% | -1.86% | -1.86% | -1.86% | -1.86% | -1.86% |
Performance & Financial Health Analysis: Cellebrite DI vs Klaviyo
| Metric | CLBT | KVYO |
|---|---|---|
| Market Information | ||
| Market Cap | $3.90B | $9.83B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 3,165,587 | 2,534,286 |
| 90 Day Avg. Volume | 2,043,326 | 2,125,372 |
| Last Close | $16.11 | $32.77 |
| 52 Week Range | $13.10 - $26.30 | $23.77 - $49.55 |
| % from 52W High | -38.75% | -33.86% |
| All-Time High | $26.30 (Feb 03, 2025) | $49.55 (Feb 10, 2025) |
| % from All-Time High | -38.75% | -33.86% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.32% |
| Quarterly Earnings Growth | 0.18% | 0.32% |
| Financial Health | ||
| Profit Margin (TTM) | -0.35% | -0.06% |
| Operating Margin (TTM) | 0.15% | -0.11% |
| Return on Equity (TTM) | -0.82% | -0.06% |
| Debt to Equity (MRQ) | 5.47 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.67 | $3.66 |
| Cash per Share (MRQ) | $1.93 | $3.12 |
| Operating Cash Flow (TTM) | $161.08M | $168.96M |
| Levered Free Cash Flow (TTM) | $122.92M | $186.32M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Cellebrite DI vs Klaviyo
| Metric | CLBT | KVYO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.09 | -192.76 |
| Forward P/E | 39.88 | 58.52 |
| PEG Ratio | 39.88 | -0.55 |
| Price to Sales (TTM) | 8.93 | 9.12 |
| Price to Book (MRQ) | 9.55 | 8.95 |
| Market Capitalization | ||
| Market Capitalization | $3.90B | $9.83B |
| Enterprise Value | $3.44B | $8.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.88 | 8.12 |
| Enterprise to EBITDA | 46.15 | -96.03 |
| Risk & Other Metrics | ||
| Beta | 1.27 | N/A |
| Book Value per Share (MRQ) | $1.67 | $3.66 |
Financial Statements Comparison: Cellebrite DI vs Klaviyo
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CLBT | KVYO |
|---|---|---|
| Revenue/Sales | $113.28M | $293.12M |
| Cost of Goods Sold | $17.68M | $71.24M |
| Gross Profit | $95.60M | $221.88M |
| Research & Development | $28.61M | $72.46M |
| Operating Income (EBIT) | $14.42M | $-31.33M |
| EBITDA | $17.01M | $-27.40M |
| Pre-Tax Income | $20.79M | $-22.48M |
| Income Tax | $1.32M | $1.80M |
| Net Income (Profit) | $19.48M | $-24.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CLBT | KVYO |
|---|---|---|
| Cash & Equivalents | $90.48M | $888.43M |
| Total Current Assets | $523.48M | $1.01B |
| Total Current Liabilities | $287.80M | $192.82M |
| Long-Term Debt | $6.39M | $84.12M |
| Total Shareholders Equity | $363.49M | $1.06B |
| Retained Earnings | $-147.46M | $-859.27M |
| Property, Plant & Equipment | $28.03M | $90.82M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CLBT | KVYO |
|---|---|---|
| Operating Cash Flow | $28.07M | $36.85M |
| Capital Expenditures | $-2.34M | $-2.69M |
| Free Cash Flow | $18.54M | $6.62M |
| Debt Repayment | N/A | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CLBT | KVYO |
|---|---|---|
| Shares Short | 3.63M | 5.50M |
| Short Ratio | 2.40 | 4.80 |
| Short % of Float | 0.03% | 0.05% |
| Average Daily Volume (10 Day) | 3,165,587 | 2,534,286 |
| Average Daily Volume (90 Day) | 2,043,326 | 2,125,372 |
| Shares Outstanding | 234.52M | 272.76M |
| Float Shares | 112.43M | 111.74M |
| % Held by Insiders | 0.45% | 0.00% |
| % Held by Institutions | 0.50% | 0.89% |
Dividend Analysis & Yield Comparison: Cellebrite DI vs Klaviyo
| Metric | CLBT | KVYO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |